MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2023.1128172

Медицинская библиотека · Frontiers in immunology · 2023

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.

Liu Yanfei, Song Yuqin, Zuo Shubo, Zhang Xian, Liu Hui, Wang Jingwen, Wang Jingbo, Tang Yongjing, Zheng Wen, Ying Zhitao, Ping Lingyan, Zhang Chen, Wu Meng, Zhu Jun, Xie Yan

Клиническое исследование II фазыМногоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

INTRODUCTION

The treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r PTCL.

METHODS

Eligible patients with r/r PTCL were enrolled and received camrelizumab 200 mg intravenously every 2 weeks and apatinib 500 or 250 mg orally once daily, 4 weeks as a cycle. The primary endpoint was overall response rate (ORR).

RESULTS

A total of 20 patients were enrolled and received study medications in the study, with a median number of prior treatment line of 3 (range 1-6). At the cutoff date of March 4, 2022, the median follow-up was 27.2 months (range: 0.5-39.9), and three patients remained on treatment. Six patients had early discontinuation without tumor response evaluation. For all patients, the ORR was 30% (6/20) (95% confidence interval [CI], 11.9% to 54.3%), with two patients (10%) achieving complete response. The median progression-free survival (PFS) and median overall survival for all patients were 5.6 months (95% CI, 1.8 to not reached) and 16.7 months (95% CI, 2.8 to not reached), respectively. Patients with PD-L1 expression ≥50% (3 patients) had a numerically higher ORR and longer median PFS than those with PD-L1 expression < 50% (5 patients). The most commonly reported grade 3 or higher adverse events were hyperlipidemia (15%), hypokalemia (15%) and anemia (15%). No treatment-related deaths occurred.

DISCUSSION: In this study, PD-1 inhibitors plus low-dose antiangiogenic drugs presented preliminary antitumor activity and manageable toxicity in patients with r/r PTCL.

Для цитирования: Liu Yanfei, Song Yuqin, Zuo Shubo, Zhang Xian, Liu Hui, Wang Jingwen, Wang Jingbo, Tang Yongjing, Zheng Wen, Ying Zhitao, Ping Lingyan, Zhang Chen, Wu Meng, Zhu Jun, Xie Yan. Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.. Frontiers in immunology. 2023. DOI: 10.3389/fimmu.2023.1128172.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.